

Nataschia Campostrini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11199592/publications.pdf>

Version: 2024-02-01

48
papers

2,502
citations

185998

28
h-index

243296

44
g-index

48
all docs

48
docs citations

48
times ranked

3456
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | A single dialysis session of hemodiafiltration with sorbent-regenerated endogenous ultrafiltrate reinfusion (HFR) removes hepcidin more efficiently than bicarbonate hemodialysis: a new approach to containing hepcidin burden in dialysis patients?. <i>Journal of Nephrology</i> , 2018, 31, 297-306. | 0.9 | 8 |
| 2 | Disturbed iron metabolism in erythropoietic protoporphyria and association of GDF15 and gender with disease severity. <i>Journal of Inherited Metabolic Disease</i> , 2017, 40, 433-441. | 1.7 | 20 |
| 3 | Identification of novel mutations in hemochromatosis genes by targeted next generation sequencing in Italian patients with unexplained iron overload. <i>American Journal of Hematology</i> , 2016, 91, 420-425. | 2.0 | 22 |
| 4 | Toward Worldwide Hepcidin Assay Harmonization: Identification of a Commutable Secondary Reference Material. <i>Clinical Chemistry</i> , 2016, 62, 993-1001. | 1.5 | 73 |
| 5 | Serum Hepcidin and Iron Absorption in Paediatric Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 566-574. | 0.6 | 43 |
| 6 | Detection of a rare mutation in the ferroportin gene through targeted next generation sequencing. <i>Blood Transfusion</i> , 2016, 14, 531-534. | 0.3 | 7 |
| 7 | Does Tmprss6 RS855791 Polymorphism Contribute to Iron Deficiency in Treated Celiac Disease?. <i>American Journal of Gastroenterology</i> , 2015, 110, 200-202. | 0.2 | 23 |
| 8 | Iron deficiency in the elderly population, revisited in the hepcidin era. <i>Frontiers in Pharmacology</i> , 2014, 5, 83. | 1.6 | 97 |
| 9 | Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo. <i>Blood</i> , 2014, 123, 1564-1573. | 0.6 | 62 |
| 10 | Hepcidin levels in chronic hemodialysis patients: a critical evaluation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 613-9. | 1.4 | 27 |
| 11 | Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo. <i>Biochemical Pharmacology</i> , 2014, 92, 467-475. | 2.0 | 38 |
| 12 | The A736V Tmprss6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: Tmprss6 and hepcidin in hemodialysis. <i>BMC Nephrology</i> , 2013, 14, 48. | 0.8 | 20 |
| 13 | Serum hepcidin levels and muscle iron proteins in humans injected with low or high dose erythropoietin. <i>European Journal of Haematology</i> , 2013, 91, 74-84. | 1.1 | 23 |
| 14 | Serum Hepcidin in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2166-2172. | 0.9 | 46 |
| 15 | Iron Status Independently Associates With Bone Mineral Density At Population Level. Insights From The Val Borbera Study. <i>Blood</i> , 2013, 122, 4672-4672. | 0.6 | 0 |
| 16 | Serum levels of the hepcidin-20 isoform in a large general population: The Val Borbera study. <i>Journal of Proteomics</i> , 2012, 76, 28-35. | 1.2 | 29 |
| 17 | Increased Serum Hepcidin Levels in Subjects with the Metabolic Syndrome: A Population Study. <i>PLoS ONE</i> , 2012, 7, e48250. | 1.1 | 68 |
| 18 | Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. <i>European Journal of Haematology</i> , 2012, 89, 87-93. | 1.1 | 91 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Hepcidin Inhibition by Modified Heparins without Anticoagulant Activity. <i>Blood</i> , 2012, 120, 483-483. | 0.6 | 0 |
| 20 | Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes. <i>PLoS ONE</i> , 2011, 6, e23109. | 1.1 | 95 |
| 21 | TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in normal individuals. <i>Blood</i> , 2011, 118, 4459-4462. | 0.6 | 97 |
| 22 | Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations. <i>Journal of Medical Genetics</i> , 2011, 48, 629-634. | 1.5 | 84 |
| 23 | A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. <i>Haematologica</i> , 2011, 96, 500-506. | 1.7 | 70 |
| 24 | Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. <i>Blood</i> , 2011, 117, 997-1004. | 0.6 | 127 |
| 25 | Serum Hepcidin Levels Correlate with Phenotypes of the Metabolic Syndrome At Population Level. <i>Blood</i> , 2011, 118, 348-348. | 0.6 | 10 |
| 26 | Hepcidin assay in serum by SELDI-TOF-MS and other approaches. <i>Journal of Proteomics</i> , 2010, 73, 527-536. | 1.2 | 47 |
| 27 | Evaluation of Hepcidin Isoforms in Hemodialysis Patients by a Proteomic Approach Based on SELDI-TOF MS. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-7. | 3.0 | 33 |
| 28 | Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3996-4002. | 0.4 | 82 |
| 29 | Hepcidin Levels and Their Determinants In Different Types of Myelodysplastic Syndromes. <i>Blood</i> , 2010, 116, 4250-4250. | 0.6 | 0 |
| 30 | HFE Mutations Modulate the Effect of Iron on Serum Hepcidin-25 in Chronic Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1331-1337. | 2.2 | 27 |
| 31 | Reduced serum hepcidin levels in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2009, 51, 845-852. | 1.8 | 148 |
| 32 | High resolution preparation of monocyte-derived macrophages (MDM) protein fractions for clinical proteomics. <i>Proteome Science</i> , 2009, 7, 4. | 0.7 | 8 |
| 33 | Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. <i>Haematologica</i> , 2009, 94, 1748-1752. | 1.7 | 161 |
| 34 | Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin. <i>Blood</i> , 2009, 113, 6707-6715. | 0.6 | 70 |
| 35 | Iron Metabolism and Erythropoietic Stress in Myelodysplastic Syndromes.. <i>Blood</i> , 2009, 114, 1752-1752. | 0.6 | 1 |
| 36 | Application of partial least squares discriminant analysis and variable selection procedures: a 2D-PAGE proteomic study. <i>Analytical and Bioanalytical Chemistry</i> , 2008, 390, 1327-1342. | 1.9 | 48 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Acquired iron overload associated with antitransferrin monoclonal immunoglobulin: A case report. American Journal of Hematology, 2008, 83, 932-934. | 2.0 | 6 |
| 38 | Clinical, pathological, and molecular correlates in ferroportin disease: A study of two novel mutations. Journal of Hepatology, 2008, 49, 664-671. | 1.8 | 39 |
| 39 | Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-hemochromatosis. Blood Cells, Molecules, and Diseases, 2008, 40, 347-352. | 0.6 | 54 |
| 40 | Advances in Quantitative Hepcidin Measurements by Time-of-Flight Mass Spectrometry. PLoS ONE, 2008, 3, e2706. | 1.1 | 176 |
| 41 | Results of the First International Round Robin for the Quantification of Urinary and Plasma Hepcidin: Need for Standardization. Blood, 2008, 112, 120-120. | 0.6 | 7 |
| 42 | Measurement of Urinary Hepcidin Levels by SELDI-TOF-MS in HFE-Hemochromatosis.. Blood, 2007, 110, 2668-2668. | 0.6 | 0 |
| 43 | Numerical approaches for quantitative analysis of two-dimensional maps: A review of commercial software and home-made systems. Proteomics, 2005, 5, 654-666. | 1.3 | 98 |
| 44 | Spot overlapping in two-dimensional maps: A serious problem ignored for much too long. Proteomics, 2005, 5, 2385-2395. | 1.3 | 130 |
| 45 | Proteome analysis in the clinical chemistry laboratory: Myth or reality?. Clinica Chimica Acta, 2005, 357, 123-139. | 0.5 | 99 |
| 46 | Proteomic analysis of an orthotopic neuroblastoma xenograft animal model*1. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 808, 279-286. | 1.2 | 14 |
| 47 | Study of proteomic changes associated with healthy and tumoral murine samples in neuroblastoma by principal component analysis and classification methods. Clinica Chimica Acta, 2004, 345, 55-67. | 0.5 | 39 |
| 48 | Comparative two-dimensional mapping of prion protein isoforms in human cerebrospinal fluid and central nervous system. Electrophoresis, 2002, 23, 339-346. | 1.3 | 35 |